Apyx Medical Valuation
Is BOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BOV (€1.34) is trading above our estimate of fair value (€0.08)
Significantly Below Fair Value: BOV is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BOV?
Other financial metrics that can be useful for relative valuation.
| What is BOV's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$51.97m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | -2.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BOV's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
NN6 NanoRepro | 1.6x | n/a | €23.1m |
GME Geratherm Medical | 0.9x | -6.2% | €22.1m |
PUS PULSION Medical Systems | 4.9x | n/a | €144.3m |
AAQ1 aap Implantate | 0.8x | 11.0% | €9.1m |
BOV Apyx Medical | 1x | 12.8% | €52.0m |
Price-To-Sales vs Peers: BOV is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does BOV's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Sales vs Industry: BOV is good value based on its Price-To-Sales Ratio (1x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is BOV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1x |
| Fair PS Ratio | 1.4x |
Price-To-Sales vs Fair Ratio: BOV is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.34 | €3.34 +149.2% | 69.9% | €7.37 | €1.84 | n/a | 4 |
| Apr ’25 | €1.21 | €3.34 +175.9% | 69.9% | €7.37 | €1.84 | n/a | 4 |
| Mar ’25 | €1.89 | €4.29 +126.9% | 66.2% | €8.27 | €1.84 | n/a | 3 |
| Feb ’25 | €2.02 | €4.29 +112.3% | 66.2% | €8.27 | €1.84 | n/a | 3 |
| Jan ’25 | €2.36 | €4.45 +88.8% | 56.4% | €8.44 | €1.88 | n/a | 4 |
| Dec ’24 | €2.10 | €4.45 +112.1% | 56.4% | €8.44 | €1.88 | n/a | 4 |
| Nov ’24 | €2.16 | €7.45 +245.0% | 26.3% | €9.46 | €4.26 | n/a | 4 |
| Oct ’24 | €2.96 | €7.19 +143.0% | 26.3% | €9.14 | €4.11 | n/a | 4 |
| Sep ’24 | €4.24 | €7.19 +69.7% | 26.3% | €9.14 | €4.11 | n/a | 4 |
| Aug ’24 | €5.00 | €6.90 +38.1% | 29.4% | €8.91 | €3.56 | n/a | 4 |
| Jul ’24 | €5.75 | €7.00 +21.8% | 34.2% | €9.14 | €3.65 | n/a | 3 |
| Jun ’24 | €5.85 | €7.33 +25.3% | 25.0% | €9.16 | €5.50 | n/a | 2 |
| May ’24 | €3.00 | €5.47 +82.3% | 49.1% | €9.12 | €2.73 | n/a | 3 |
| Apr ’24 | €2.42 | €5.68 +134.9% | 49.1% | €9.47 | €2.84 | €1.21 | 3 |
| Mar ’24 | €2.92 | €5.68 +94.7% | 49.1% | €9.47 | €2.84 | €1.89 | 3 |
| Feb ’24 | €2.60 | €5.68 +118.6% | 49.1% | €9.47 | €2.84 | €2.02 | 3 |
| Jan ’24 | €2.04 | €5.68 +178.6% | 49.1% | €9.47 | €2.84 | €2.36 | 3 |
| Dec ’23 | €1.75 | €7.52 +329.8% | 43.0% | €9.81 | €2.94 | €2.10 | 3 |
| Nov ’23 | €5.00 | €14.68 +193.7% | 16.2% | €17.92 | €11.95 | €2.16 | 4 |
| Oct ’23 | €4.52 | €14.68 +224.9% | 16.2% | €17.92 | €11.95 | €2.96 | 4 |
| Sep ’23 | €5.85 | €14.72 +151.7% | 16.2% | €17.97 | €11.98 | €4.24 | 4 |
| Aug ’23 | €9.10 | €12.33 +35.4% | 35.1% | €16.76 | €5.92 | €5.00 | 4 |
| Jul ’23 | €5.65 | €10.49 +85.7% | 31.7% | €14.92 | €5.60 | €5.75 | 4 |
| Jun ’23 | €5.65 | €10.49 +85.7% | 31.7% | €14.92 | €5.60 | €5.85 | 4 |
| May ’23 | €3.84 | €13.79 +259.1% | 20.0% | €16.55 | €11.03 | €3.00 | 2 |
| Apr ’23 | €5.80 | €15.02 +159.0% | 20.4% | €18.02 | €10.81 | €2.42 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.